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diseases and could potentially be used as targets in therapeutic interventions.

Lipoxygenases (LOXs)2 are a class of widely distributed nonheme iron-containing enzymes that catalyze the regio- and stereospecific peroxidation of polyunsaturated fatty acids containing one or more (cis,cis)-1,4-pentadiene segments within the
aliphatic chain (1–5). The primary products of LOX-catalyzed
reactions are typically chiral fatty acid hydroperoxides, which
are rapidly transformed intracellularly by peroxidases into their
corresponding hydroxyl analogs. Both hydroperoxyl lipoxygenase products and their reduced hydroxyl counterparts have
been shown to serve a plethora of signaling functions in multiple cell types, tissues, and disease states (6 –11).
The most abundant source of 12-LOX is blood platelets (4).
Similarly, the most thoroughly studied mammalian lipoxygenase is the human platelet-type 12-LOX, which initially
abstracts hydrogen at the C10 position of arachidonic acid
(AA). Next, the stereospecific incorporation of molecular oxygen occurs at the C12 position resulting in the production of
12(S)-hydroperoxy-eicosatetraenoic acid (12(S)-HpETE) (5).
The hydroperoxide is readily reduced intracellularly to generate 12(S)-hydroxy-eicosatetraenoic acid (12-HETE) (12, 13).
Both 12(S)-HpETE and 12(S)-HETE are potent signaling
ligands for multiple cellular receptors (e.g. G protein– coupled
receptors) and also participate in nonreceptor-mediated regulatory functions as well (14, 15). Previous work demonstrated
that 12-HpETE and 12-HETE promote the formation/activation of intracellular signaling complexes (16, 17). In addition,
12-LOX product 12-HETE can be re-esterified into lysophospholipids by acyl-CoA– dependent acyltransferases generating
oxidized phospholipids with their own repertoire of unique
biologic properties (6, 18). For example, incorporation of
hydroxylated acyl chain lipids into cellular phospholipids alters
2

The abbreviations used are: 12-LOX, 12-lipoxygenase; iPLA2␥, calcium-independent phospholipase A2␥; cPLA2␣, cytosolic phospholipase A2␣; PPH3,
triphenylphosphine; AA-LPC, arachidonoyl-lysophosphatidylcholine; AALPE, arachidonoyl-lysophosphatidylethanolamine; 12-HETE, 12-hydroxy-eicosatetraenoic acid; 12-HpETE, 12-hydroperoxy-eicosatetraenoic acid; ML355,
N-2-benzothiaoly-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide; HRAM, high resolution high mass accuracy; CID,
collision-induced dissociation; Ni-NTA, nickel-nitrilotriacetic acid; AA,
arachidonic acid.
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The canonical pathway of eicosanoid production in most
mammalian cells is initiated by phospholipase A2-mediated
release of arachidonic acid, followed by its enzymatic oxidation resulting in a vast array of eicosanoid products. However,
recent work has demonstrated that the major phospholipase
in mitochondria, iPLA2␥ (patatin-like phospholipase domain
containing 8 (PNPLA8)), possesses sn-1 specificity, with polyunsaturated fatty acids at the sn-2 position generating polyunsaturated sn-2-acyl lysophospholipids. Through strategic
chemical derivatization, chiral chromatographic separation,
and multistage tandem MS, here we first demonstrate that
human platelet-type 12-lipoxygenase (12-LOX) can directly
catalyze the regioselective and stereospecific oxidation of
2-arachidonoyl-lysophosphatidylcholine (2-AA-LPC) and
2-arachidonoyl-lysophosphatidylethanolamine (2-AA-LPE).
Next, we identified these two eicosanoid-lysophospholipids
in murine myocardium and in isolated platelets. Moreover,
we observed robust increases in 2-AA-LPC, 2-AA-LPE, and
their downstream 12-LOX oxidation products, 12(S)-HETELPC and 12(S)-HETE-LPE, in calcium ionophore (A23187)stimulated murine platelets. Mechanistically, genetic ablation of iPLA2␥ markedly decreased the calcium-stimulated
production of 2-AA-LPC, 2-AA-LPE, and 12-HETE-lysophospholipids in mouse platelets. Importantly, a potent and
selective 12-LOX inhibitor, ML355, significantly inhibited
the production of 12-HETE-LPC and 12-HETE-LPE in activated platelets. Furthermore, we found that aging is accompanied by significant changes in 12-HETE-LPC in murine
serum that were also markedly attenuated by iPLA2␥ genetic
ablation. Collectively, these results identify previously unknown iPLA2␥-initiated signaling pathways mediated by
direct 12-LOX oxidation of 2-AA-LPC and 2-AA-LPE. This
oxidation generates previously unrecognized eicosanoid-lysophospholipids that may serve as biomarkers for age-related
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Herein, we report the ability of platelet-type 12-LOX to efficiently catalyze the regioselective and stereospecific oxidization of both 2-AA-LPC and 2-AA-LPE into 12(S)-HpETE-LPC
and 12(S)-HpETE-LPE, which are readily reduced to 12(S)HETE-LPC and 12(S)-HETE-LPE both in vitro and in vivo,
respectively. In addition, we show that multiple eicosanoid-lysophospholipid molecular species are present in myocardium
and platelets with dynamic alterations after cellular stimulation. Finally, we demonstrated that aging in mice is accompanied by increased levels of 12-HETE-LPC in serum that are
attenuated by genetic ablation of iPLA2␥. Collectively, these
results identify previously unknown iPLA2␥-initiated signaling
pathways mediated by direct 12-LOX oxidation of 2-arachidonoyl-lysophospholipids to generate previously unrecognized
eicosanoid-lysophospholipid metabolites in critical cells of the
cardiovascular system that could potentially serve as biomarkers of disease and inflammation during aging.

Results
12-LOX efficiently catalyzes the regioselective and
stereospecific oxidation of 2-AA-LPC and 2-AA-LPE to
12(S)-HpETE-lysophospholipids
To test the hypothesis that 2-AA-lysophospholipids are efficient substrates for oxidation by 12-LOX, we first cloned,
expressed, and purified recombinant human platelet-type
12-LOX as described under “Experimental procedures.” Additionally, we synthesized and purified 2-AA-LPC and 2-AA-LPE
as previously described (34, 37–39). Next, we incubated 2-AALPC or 2-AA-LPE with purified 12-LOX. The reaction products were separated by HPLC and identified by high resolution
high mass accuracy (HRAM) MS. Mass spectrometric analysis
demonstrated the generation of previously unknown metabolites whose accurate masses and fragmentation patterns corresponded to the anticipated hydroperoxyl-oxidized eicosanoidlysophospholipids (m/z 576.3291 for HpETE-LPC and m/z
534.2820 for HpETE-LPE, respectively) (Fig. 1, A and B). Multistage tandem MS with collision-induced dissociation (CID)
fragmentation identified multiple informative fragment ions
with the expected cleavage at the labile hydroperoxide bond
and cleavage at the C12 position. Furthermore, accurate
masses of the product ions were within 5 ppm of theoretical
values and correspond to the likely fragmentation pathways
(Figs. S1 and S2). Collectively, these experiments established
the C12 regiochemistry of the 12-LOX– oxidized 2-AA-lysophospholipid products leading to their provisional assignments as 12-HpETE-LPC and 12-HpETE-LPE (Fig. 1, C–F).
To further substantiate the proposed assignments by an independent method, we prepared and purified human recombinant cytosolic phospholipase A2␣. Next, we treated the
12-LOX– generated eicosanoid-lysophospholipids with the
purified recombinant cPLA2␣ to hydrolyze the sn-2 acyl chain
(40 –42). The released fatty acids were derivatized with N-(4amino-methylphenyl)-pyridinium (AMPP), and the resultant
AMPP-eicosanoids were separated by RP-HPLC prior to identification by HRAM MS (43). The elution times and fragmentation
patterns of the AMPP-derivatized eicosanoids originating from
the 12-LOX–generated eicosanoid-lysophospholipids were indis-
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membrane bilayer molecular dynamics and has multiple effects
on complex transmembrane protein assembly through serving
as a molecular scaffold (19). Remarkably, 12-LOX loss of function, through either genetic ablation or by pharmacologic inhibition, can reverse islet ␤-cell dysfunction and restore normal
insulin secretion (20 –26). Moreover, 12-HETE activates platelets thereby serving as an autocrine and paracrine amplification
cascade (27–31). Despite the profound biological and clinical
importance of the downstream oxidized products of 12-LOX,
investigations have been limited to previously known substrates for oxidation (i.e. arachidonic acid). Thus, the roles of
12-LOX in generating previously unknown metabolites that
serve novel signaling functions remain to be clarified.
Recent structural studies of 12-LOX have revealed the fatty
acid pentadiene target is positioned in close spatial proximity to
the nonheme iron facilitating regiospecific hydrogen radicubal
abstraction and stereospecific reaction of the radical intermediate with molecular oxygen to collectively result in the production of the chiral 12(S)-HpETE product (5, 24, 32, 33). Notably,
the crystal structure of the 12-LOX catalytic domain possesses
a U-shaped substrate-binding site that facilitates the precise
positioning of the C10 hydrogens in arachidonic acid for the
regioselective and stereospecific oxidization of AA resulting in
the production of 12(S)-HpETE (32). The open U-shape substrate-binding site of 12-LOX appeared large enough to accommodate the associated polar head group of 2-AA-lysophospholipids. Accordingly, we hypothesized that the entry of the
arachidonoyl moiety of 2-AA-lysophospholipids into the active
site and stereospecific oxidation appeared likely. Furthermore,
the presence of the zwitterionic polar head group in 2-AA-LPC
or 2-AA-LPE may allow further molecular interactions to stabilize the arachidonate moiety of 2-AA-lysophospholipids in
the active site.
Previously, we identified a novel calcium-independent phospholipase, phospholipase A2␥ (also known as PNPLA8) that
catalyzes the highly regioselective (over 90%) cleavage of phospholipids at the sn-1 position (with a polyunsaturated fatty acid
at the sn-2 position) resulting in the generation of 2-acyl-lysophospholipids (34). To gain further insight into the role of
iPLA2␥ in cardiac function, we generated germline iPLA2␥⫺/⫺
mice by eliminating the active site of the enzyme. Genetic ablation of iPLA2␥ resulted in growth retardation, compromised
thermal adaption to cold, reduced exercise endurance, and a
surprising ability of iPLA2␥⫺/⫺ mice to remain refractory to the
development of obesity and insulin resistance during prolonged
HF feeding. We did not observe significant changes of the longevity between WT and iPLA2␥⫺/⫺ mice (35, 36). Moreover,
lipidomic analysis revealed that genetic ablation of iPLA2␥⫺/⫺
resulted in over a 60% decrease in the production of 2-[14C]arachidonoyl-LPC from 1-palmitoyl 2-[14C]arachidonoyl-PC in
incubations with mitochondrial homogenates prepared from
iPLA2␥⫺/⫺ mice (35). The regiospecificity of iPLA2␥ for the
sn-1 position of polyunsaturated phospholipids suggested the
existence of a previously unknown signaling pathway initiated
by the generation of 2-arachidonoyl-lysophosphatidylcholine,
which serves as a signaling node for multiple lipid 2nd messenger cascades (37, 38).

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout

tinguishable from authentic eicosanoid fatty acid standards,
thereby confirming the proposed structural assignments (Fig. 2).
Determination of the chirality of 12-LOX– generated
eicosanoid-lysophospholipids
The stereochemistry of the 12-LOX– generated eicosanoidlysophospholipid products were determined using chiral HPLC
to separate the (R)- and (S)-stereoisomers of the AMPP-derivatized eicosanoids by comparisons with authentic standards.
Mass spectrometric analysis of the separated reaction products
revealed that 12-LOX–mediated oxidation of the arachidonoyl
group of 2-AA-lysophospholipids yielded almost exclusively
(⬎99%) the S-enantiomeric configuration (Fig. 3).
Kinetics of 12-LOX–mediated oxidation of 2-AA-LPC and
2-AA-LPE
Next, we determined the apparent kinetic values of 12-LOX–
mediated oxidation of both 2-AA-LPC and 2-AA-LPE substrates using substrate concentrations varying from 5 to 80
M. The results (Table S1) revealed that human platelet-type

12-LOX is capable of metabolizing 2-AA-LPC more rapidly than
2-AA-LPE by a factor of 1.9. Mouse platelet 12-LOX also shows
the similar trend of substrate preference but there is no statistically
significant difference under the conditions examined.
12-LOX–mediated oxidation of 2-AA-LPC and 2-AA-LPE is
potently inhibited by ML355 (N-2-benzothiazolyl-4[[(2-hydroxy-3-methoxy-phenyl)methyl]
amino]-benzenesulfonamide)
Previous work has demonstrated that ML355 is a potent
and selective inhibitor of 12-LOX–mediated generation of
12-HpETE from arachidonic acid (44). To further establish the
role of 12-LOX in the oxidation of 2-AA-lysophospholipids,
recombinant human or mouse platelet-type 12-LOX was preincubated with ML355 prior to addition of 2-AA-LPC or
2-AA-LPE substrates. Analysis of the reaction extracts by
LC-MS demonstrated that production of 12-HpETE-LPC
and 12-HpETE-LPE by either human or mouse platelet-type
12-LOX were dramatically inhibited (⬎80%) by ML355 (Fig.
4). Utilization of HRAM MS in conjunction with multistage
J. Biol. Chem. (2020) 295(16) 5307–5320
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Figure 1. Chemical characterization of 12-LOX mediated oxidation products of 2-AA-LPC and 2-AA-LPE. Purified recombinant human platelet-type
12-LOX (2 g) was incubated with 2-AA-LPC (10 M) or 2-AA-LPE (10 M) in 100 mM Tris-HCl buffer (pH 7.2) at 30 °C for 5 min. The reaction was terminated
by addition of methanol and acidified to pH 4 with glacial acetic acid. The reaction products were then purified by solid-phase extraction followed by
separation on a C18 HPLC column prior to analysis utilizing an LTQ-Orbitrap mass spectrometer with a mass resolution of 30,000 at m/z 400 in the
positive ion mode. A, extracted ion chromatograms (with a 3 ppm mass window) for the identified metabolic products of 12-HpETE-LPC (m/z 576.3296)
and 12-HETE-LPC (m/z 560.3347) are shown; triphenylphosphine (PPH3) was used to reduce 12-HpETE-LPC to 12-HETE-LPC. CTRL, negative control
reaction without 12-LOX. B, extracted ion chromatograms (with a 3 ppm mass window) for the identified metabolic products of 12-HpETE-LPE (m/z
534.2826) and 12-HETE-LPE (m/z 518.2877) are shown. PPH3 was used to reduce 12-HpETE-LPE to 12-HETE-LPE. CTRL, negative control reaction without
12-LOX, C, MS2 spectrum of the parent M⫹ ion (12-HpETE-LPC) at m/z 576.3. D, resultant MS3 spectrum of the fragment ions derived from the ion at m/z
558.3 (576.3 3 558.3). E, MS2 spectrum of the parent M⫹ ion (12-HpETE-LPE) at m/z 534.3. F, resultant MS3 spectrum of the fragment ions derived from
the ion at m/z 516.3 (534.3 3 516.3). The chemical identities of the fragmentation product ions are described under supporting Figs. S1 and S2.

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout
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Figure 2. Identification of the eicosanoid-lysophospholipids generated by 12-LOX– catalyzed oxidation of 2-AA-LPC and 2-AA-LPE. 12-LOX–
generated eicosanoid-lysophospholipids were treated with cPLA2␣ and the resultant released eicosanoids were chemically derivatized with AMPP, separated
on a C18 HPLC column and analyzed by MS. A, retention time chromatogram of standard reference of AMPP-derivatized 12-HpETE. B, retention time chromatogram of the AMPP-derivatized eicosanoid product generated by cPLA2␣-mediated hydrolysis of the 12-LOX oxidation product of 2-AA-LPC. C, retention time
chromatogram of the AMPP-derivatized eicosanoid product generated by cPLA2␣-mediated hydrolysis of the 12-LOX oxidation product of 2-AA-LPE. D, MS/MS
product ion spectrum of standard reference 12-HpETE derivatized with AMPP. E, MS/MS product ion spectrum of the eicosanoid-AMPP derivative obtained
from 12-LOX–mediated oxidation of 2-AA-LPC. F, MS/MS product ion spectrum of the eicosanoid-AMPP derivative obtained from 12-LOX–mediated oxidation
of 2-AA-LPE. G, proposed fragmentation pathways upon CID leading to the observed product ions for 12-HpETE-AMPP. The measured product ions’ masses are
within 2 ppm (parts per million) error relative to the calculated theoretical masses.

tandem MS CID fragmentation analysis and pharmacologic
inhibition collectively identify 12-LOX as an efficient enzymatic mediator of the production of the identified eicosanoid-lysophospholipids from 2-arachidonoyl-lysophospholipids. These novel moieties have the potential to serve as
metabolic and signaling nodes for a wide range of eicosanoid
phospholipids after acyl transferase activity (or transacylase

5310 J. Biol. Chem. (2020) 295(16) 5307–5320

activity) or alternatively through the release of nonesterified
eicosanoids after hydrolysis.
Genetic ablation of iPLA2␥ markedly attenuates the production
of 12-HETE-lysophospholipids in murine myocardium
To determine whether the identified 12-LOX– generated
eicosanoid-lysophospholipids were present in murine myocar-
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Figure 3. Chiral-phase HPLC-MS analyses of the 12-HETE-AMPP derivatives generated by 12-LOX– catalyzed oxidation of 2-AA-LPC and 2-AA-LPE.
12-LOX generated hydroperoxy eicosanoid-lysophospholipids were treated with cPLA2␣ and then reduced by triphenylphosphine. Next, the resultant eicosanoid products were derivatized with AMPP and analyzed by chiral-phase HPLC-MS. A, chromatogram of standard racemic AMPP-derivatized 12(R/S)-HETE. B,
MS/MS product ion spectrum of standard reference racemic AMPP-derivatized 12(R/S)-HETE. C, chromatogram of standard AMPP-derivatized 12(S)-HETE. D,
MS/MS product ion spectrum of standard 12(S)-HETE; E, chromatogram of the AMPP-derivatized eicosanoid(s) originating from the 12-LOX oxidation products
of 2-AA-LPC. F, MS/MS product ion spectrum of the AMPP-derivatized eicosanoid(s) originating from the 12-LOX oxidation products of 2-AA-LPC. G, chromatogram of the AMPP-derivatized eicosanoid(s) originating from the 12-LOX oxidation products of 2-AA-LPE. H, MS/MS product ion spectrum of the AMPPderivatized eicosanoid(s) originating from the 12-LOX oxidation products of 2-AA-LPE.

dium and if their production depended upon iPLA2␥, we compared WT versus germline iPLA2␥⫺/⫺ mice generated in our
laboratory (35). Lipids from freshly isolated murine heart tissue

of WT and germline iPLA2␥⫺/⫺ mice were extracted using a
modified Bligh and Dyer procedure, enriched for eicosanoidlysophospholipids by solid-phase extraction, and analyzed by
J. Biol. Chem. (2020) 295(16) 5307–5320
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LC-MS/MS as described under “Experimental procedures.”
Genetic ablation of iPLA2␥ resulted in a marked reduction of
both 2-AA-LPC and 2-AA-LPE in murine myocardium (Fig.
5A). Furthermore, the amounts of their respective 12-LOX oxidation products, 12-HETE-LPC and 12-HETE-LPE, were also
markedly decreased in myocardial tissue from iPLA2␥⫺/⫺ mice
compared with their WT littermates (Fig. 5B). The results demonstrate that 12-HETE-lysophospholipids are present in
murine myocardium and that their production is initiated by
iPLA2␥.
Calcium ionophore stimulates the production of 12-HETElysophospholipids in murine platelets, which is inhibited by
genetic knockout of iPLA2␥
Next, to mechanistically identify the role of iPLA2␥ in the
release of 2-AA-lysophospholipids and subsequent production
of 12-LOX eicosanoid-lysolipids in intact platelets, we stimulated murine platelets with calcium ionophore. Platelets from
WT and germline iPLA2␥⫺/⫺ mice were treated with either the

5312 J. Biol. Chem. (2020) 295(16) 5307–5320

Figure 5. Genetic ablation of iPLA2␥ markedly attenuates the production
of 2-AA-lysophospholipids and 12-HETE-lysophospholipids in murine
myocardium. Murine myocardial tissue was isolated from wildtype (WT) and
iPLA2␥ knockout (KO) mice and flash frozen in liquid nitrogen prior to lipid
extraction using a modified Bligh and Dyer (56) procedure. The myocardial
lipid extracts were purified by solid-phase extraction and analyzed by HPLCMS/MS. A, contents of 2-AA-LPC and 2-AA-LPE in mouse heart tissue from WT
and KO mice. B, contents of 12-HETE-LPC and 12-HETE-LPE in mouse heart
tissue from WT and KO mice. Data are expressed as mean ⫾ S.E. of six independent replicates. Statistical analyses were performed using an unpaired
two-tailed Student’s t test. p values for the bracketed data sets are as indicated (**, p ⬍ 0.01; ***, p ⬍ 0.001).

vehicle (DMSO) alone or the calcium ionophore A23187 (1.0
M). Ionophore-mediated calcium influx induced a robust
increase in the levels of both 2-AA-LPC and 2-AA-LPE in WT
platelets, which was markedly decreased in iPLA2␥ knockout
platelets in comparisons to WT littermate controls (Fig. 6, A
and B). Notably, abundant amounts of 1-AA-LPC and 1-AALPE were also detected in platelets under the experimental conditions employed (Fig. S3). Previous work has indicated that the
rate of ␣-hydroxy migration from the sn-2 carbon to the sn-1
carbon is influenced by multiple factors including pH and ionic
strength (45). In the current work, we investigated acyl migra-
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Figure 4. Platelet-type 12-LOX–mediated oxidation of 2-AA-LPC and
2-AA-LPE is inhibited by ML355. Purified recombinant human or mouse
12-LOX was incubated with either 2-AA-LPC (10 M) or 2-AA-LPE (10 M) at
30 °C for the indicated times. The reaction was then terminated with methanol and the resultant products were enriched by solid-phase extraction prior
to analysis by LC-MS. For inhibition experiments, purified recombinant
12-LOX was preincubated with ML355 (1.0 M) for 15 min prior to incubation
with 2-AA-LPC or 2-AA-LPE. A, time course of 12-LOX–mediated oxidation of
2-AA-LPC and its inhibition by ML355 ((human 12-LOX (blue triangles), mouse
12-LOX (green diamonds); human 12-LOX with ML355 (red triangles), and
mouse 12-LOX with ML355 (purple diamonds)). B, time course of 12-LOX–
mediated oxidation of 2-AA-LPE and its inhibition by ML355 ((human 12-LOX
(blue triangles), mouse 12-LOX (green diamonds), human 12-LOX with ML355
(red triangles), and mouse 12-LOX with ML355 (purple diamonds)). Data are
expressed as mean ⫾ S.E. of three replicate experiments.

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout

tion for 2-AA-LPC and 2-AA-LPE at selected pH values (Fig.
S4). The results demonstrated that the acyl migration rate from
the sn-2 position to the sn-1 position is highly dependent upon
the pH of the solution. Although we cannot entirely rule out the
direct synthesis of 1-AA-LPC and 1-AA-LPE in vivo (i.e. diAA-PC and di-AA-PE, which can be hydrolyzed by PLA2
enzymes (e.g. cPLA2␣) to generate 1-AA-LPC and 1-AA-LPE),
we conclude that the majority of the 1-AA-lysophospholipids
detected in platelets likely result from the cellular synthesis of
2-AA-lysophospholipids followed by nonenzymatic ␣-hydroxyl acyl migration.

Importantly, the generation of 12-HETE-lysophospholipids
in platelets was increased by the influx of calcium ion, which
induced a robust increase in the levels of both 12-HETE-LPC
and 12-HETE-LPE in WT platelets (Fig. 6, C and D). In stark
contrast, genetic ablation of iPLA2␥ markedly decreased the
calcium-stimulated production of 12-LOX– derived eicosanoid-lysophospholipids in iPLA2␥⫺/⫺ platelets relative to
WT littermate controls (Fig. 6, C and D). Moreover, ML355 did
not change the production of 2-AA-LPC and -LPE, but it significantly inhibited the production of 12-HETE-LPC and -LPE
(Fig. 6).
J. Biol. Chem. (2020) 295(16) 5307–5320
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Figure 6. Calcium-dependent generation of 12-HETE-lysophospholipids in murine platelets isolated from WT and iPLA2␥ⴚ/ⴚ (KO) mice stimulated
with calcium ionophore A23187. Washed platelets were incubated in the absence or presence of the calcium ionophore A23187 (1.0 M) at 37 °C for 15 min
prior to extraction of lipids using a modified Bligh and Dyer (56) procedure and analysis by HPLC-MS/MS. For inhibition experiments, ML355 (10 M) was
preincubated for 15 min prior to addition of A23187. A and B, content of 2-AA-LPC (A) and 2-AA-LPE (B) in the absence (DMSO) (Control) or presence (A23187)
of calcium ionophore A23187 or ML355 and A23187 (ML355-A23187) in platelets from WT or KO mice. C and D, content of 12-HETE-LPC (C) and 12-HETE-LPE (D)
in the absence (DMSO) (Control) or presence (A23187) of calcium ionophore A23187 or ML355 and A23187 (ML355-A23187) in platelets from WT or KO mice.
Data are expressed as mean ⫾ S.E. of six independent replicates. Statistical analyses were performed using an unpaired two-tailed Student’s t test. Statistically
significant p values are as indicated above the bracketed data sets (**, p ⬍ 0.01; ***, p ⬍ 0.001; ****, p ⬍ 0.0001).

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout

Because calcium activates iPLA2␥ to produce 2-AA-lysophospholipids from arachidonate-containing phospholipids
(37), these results indicate that the production of 2–12–HETElysophospholipids in platelets is initiated by iPLA2␥–mediated
PLA1 hydrolysis of AA-phospholipids to produce 2-AA-lysophospholipids that can then be directly oxidized by 12-LOX to
generate 2–12–HETE-lysophospholipids (Fig. 7). Furthermore,
these results suggest that 12-HETE or its lysophospholipid
derivatives released from parent phospholipids may participate
in either autocrine or paracrine amplification cascades.
Eicosanoid-lysophospholipids increase with aging in murine
serum, demonstrate gender-related differences, and are
markedly attenuated in iPLA2␥ⴚ/ⴚ mice
Aging is known to result in substantial changes in serum
lipids (46, 47) and sex differences in free eicosanoids production have been observed (48, 49). However, alterations in eicosanoid-lysophospholipid levels during aging or comparisons of
male versus female mice have not been previously made. To
gain insight into potential age- and gender-related changes in
eicosanoid-lysophospholipid levels, we analyzed the amount of
12-HETE-LPC in serum from young (3-month-old) and old
(10-month-old) male and female WT and iPLA2␥⫺/⫺ mice.
Notably, a 2-fold increase in serum 12-HETE-LPC was
observed in 10-month-old male mice compared with 3-monthold male mice (Fig. 8). Furthermore, serum 12-HETE-LPC was
markedly attenuated in iPLA2␥⫺/⫺ male mice (⬃65% decrease)
relative to WT controls (Fig. 8). In contrast, we identified only
modestly increased amounts of 12-HETE-LPC in serum from
female mice during aging. Genetic ablation of iPLA2␥ in female
mice resulted in similar decreases relative to their WT controls
as observed in the serum of male mice (Fig. 8). Collectively,
these results demonstrate that aging is accompanied by marked
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increases in 12-HETE-LPC in male murine serum and imply
that 12-HETE-LPC may serve as a gender-specific biomarker
for various age-associated diseases.

Discussion
Previously, we demonstrated that calcium ion induces the
activation of iPLA2␥ leading to the production of 2-AA-LPC
and 2-AA-LPE (37). Remarkably 2-arachidonoyl-lysophospholipids were directly oxidized by cyclooxygenase-2 to produce
multiple eicosanoid-lysophospholipids including those containing either prostaglandin (e.g. prostaglandin E2) or other
hydroxylated polyunsaturated aliphatic acyl chains (e.g. 11(R)HETE and 15-HETE) that are major participants in signaling
processes (38). These findings led us to investigate whether
2-arachidonoyl-lysophospholipids were substrates for the
platelet-type 12-lipoxygenase, which is the predominant 12LOX in most cellular systems (50). In the present study, we
expressed and purified recombinant human platelet-type
12-LOX and demonstrated that 12-LOX regioselectively and
stereospecifically oxidizes multiple classes of 2-AA-lysophospholipids to their corresponding 12(S)-HETE-lysophospholipid derivatives. Intriguingly, 2-arachidonoyl-glycerol was not
detectably oxidized by platelet-type 12-LOX (51). In stark contrast, 2-AA-LPC and 2-AA-LPE are efficiently oxidized by
platelet-type 12-LOX. This difference demonstrates an interesting substrate specificity of platelet-type 12-LOX suggesting
that additional interaction sites for suitable orientation and efficient catalysis by platelet 12-LOX is necessary.
To mechanistically identify the enzyme(s) responsible for the
production of these previously unknown natural products, a
mouse model with germline ablation of exon 5 (encoding the
active site) of iPLA2␥ was utilized (35). Upon stimulation with
calcium ionophore, the production of both 2-AA-LPC and

Downloaded from http://www.jbc.org/ at Washington University on September 6, 2020

Figure 7. Proposed pathways of iPLA2␥ initiated production of arachidonate-containing lysophospholipids for 12-LOX–mediated generation of
eicosanoid-lysophospholipids in murine platelets. Calcium-mediated activation of mitochondrial iPLA2␥ results in the production of 2-AA-LPC and 2-AALPE, which are substrates for platelet-type 12-LOX for oxidation to 12-HpETE-LPC and 12-HpETE-LPE, respectively. The resulting hydroperoxide lysophospholipids are subsequently reduced to their corresponding hydroxyl molecular species by peroxide reductases (e.g. GSH peroxidases).

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout

2-AA-LPE were dramatically increased in WT platelets. Parallel increases were also observed in 12-HETE-LPC and
12-HETE-LPE in WT platelets stimulated with calcium ionophore. In contrast, the synthesis of 2-AA-LPC, 2-AA-LPE,
12-HETE-LPC, and 12-HETE-LPE were significantly decreased
after ionophore stimulation of platelets from iPLA2␥⫺/⫺ mice
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Figure 8. Altered levels of 12-HETE-LPC in the serum of old and young
male and female WT and iPLA2␥ⴚ/ⴚ (KO) Mice. Murine serum was collected
from young (3 months) and old (10 months) WT and iPLA2␥ KO male and
female mice. Serum lipids were extracted using a modified Bligh and Dyer (56)
procedure. The lipid extracts were purified by solid-phase extraction and analyzed for the content of 12-HETE-LPC by HPLC-MS/MS. Data are expressed as
mean ⫾ S.E. of four independent replicates. Statistical analyses were performed using an unpaired two-tailed Student’s t test. A, content of 12-HETELPC. Statistically significant p values are indicated above the bracketed data
sets; B, fold-changes relative to KO-Young females. Statistically significant p
values are indicated relative to the KO-Young female. *, p ⬍ 0.05; **, p ⬍ 0.005;
***, p ⬍ 0.001; ****, p ⬍ 0.0001.

compared with their WT controls. Moreover, ML355 significantly inhibited the production of 12-HETE-lysolipids; but the
production of 2-AA-LPC and -LPE were not changed. These
findings suggest a sequential process initiated by calcium-mediated activation of iPLA2␥ to produce 2-AA-lysophospholipids followed by their subsequent 12-LOX-catalyzed oxidation
to generate 12-(S)-HETE-lysophospholipids.
Oxidized lysophospholipids are anticipated to undergo rapid
lateral motion in the membrane facilitating two-dimensional
interactions to engage biological partners (e.g. receptors, ion
channels, etc.). Furthermore, because the membrane limits 3D
spatial interactions, membranes can serve as scaffolds for
complex assemblies of biomolecules (19, 52, 53). Thus,
12(S)-HETE-lysophospholipids are predicted to have potent
pleiotropic effects on cellular membrane structure, molecular dynamics, dipole interactions, membrane potentials, and
scaffolds in addition to serving as potential ligands to cellular
receptors.
Moreover, we note that these oxidized lysophospholipids are
also excellent substrates for sn-1 acyltransferases and transacylases, which result in the production of oxidized phospholipids
that have emerged as potent signaling molecules in many systems (54). We suggest that multiple discrete eicosanoid-lysophospholipids generate a rich repertoire of molecular entities
that can interact with specific receptors, differently modulate
membrane surface charge and protein dynamics, and potentially serve as DAMPs (damage-associated molecular patterns)
or DAMP precursors to facilitate specific cellular receptors in
injured tissues. The difficulty to demonstrate a bona fide interaction due to the rapidly changing products of this class of lipids
should be recognized. We have begun the synthesis of a nonhydrolyzable analog as well as an analog missing the sn-1 hydroxyl
to address this important point.
Previously, we demonstrated that the sn-1 vinyl ether linkage
of plasmenylcholine and plasmenylethanolamine containing
arachidonic acid at the sn-2 position can be oxidatively cleaved
by oxidized cardiolipin-activated cytochrome c to yield 2-AALPC and 2-AA-LPE, respectively (i.e. plasmalogenase activity)
(55). Thus, in addition to the production of 2-AA-lysophospholipids by iPLA2␥, it seems likely that a portion of the 2-arachidonoyl-lysophospholipids and their corresponding 12-LOX
oxidation products observed in iPLA2␥⫺/⫺ platelets is due to
cleavage of the vinyl ether linkage of plasmenylethanolamine,
which is rich in platelet membranes. Alternatively, other PLA1
activities, either known or as yet undiscovered, may contribute
to the generation of sn-2-arachidonoyl-lysophospholipids.
Additionally, these studies also demonstrate that eicosanoidlysophospholipids can be directly hydrolyzed by a variety of
intracellular phospholipases (e.g. cPLA2␣) and lysophospholipases resulting in the liberation of nonesterified eicosanoids
that are known to possess potent effects in multiple disease
states including diabetes, cancer, cardiovascular disease, and
endothelial dysfunction (6 –8).
Collectively, the present study identifies previously unknown
signaling metabolites emanating from the iPLA2␥-mediated
sn-1 hydrolysis of arachidonate-containing phosphatidylcholine and phosphatidylethanolamine. The resultant 2-arachidonoyl-lysophospholipids are subsequently oxidized directly

Eicosanoid-lysophospholipids are attenuated by iPLA2␥ knockout
by 12-LOX to generate eicosanoid-lysophospholipids (Fig. 7).
Furthermore, our results demonstrate that aging is associated
with marked alterations in 12-HETE-lysophospholipid levels in
murine serum that were markedly attenuated by iPLA2␥
genetic ablation. Finally, our results identify high concentrations of eicosanoid-lysolipids in murine serum that are age and
gender selective. Thus, these moieties or their downstream
metabolites can potentially provide new biomarkers for discovery of age-related disease states such as Alzheimer’s disease.

Expression and purification of human cPLA2␣
The cDNA encoding human cPLA2␣ was subcloned to engineer a 6-residue histidine tag, His6, at the C terminus for purification using Ni-NTA affinity chromatography. Briefly, Sf9
cells (5 ⫻ 100-ml suspension cultures at 1 ⫻ 106 cells/ml)
were infected with baculovirus-encoding recombinant
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Kinetic analysis of the 12-LOX–mediated oxidation of
2-AA-LPC or 2-AA-LPE
Time course experiments—Human or mouse platelet-type
recombinant 12-LOX (mouse platelet-type 12-LOX was purchased from Cayman Chemicals Co., Ann Arbor, MI) (2 g)
was incubated with either 2-AA-LPC or 2-AA-LPE (10 M) in
400 l of 100 mM Tris-HCl buffer (pH 7.2) containing 10%
glycerol at 30 °C for various times. The reaction was then terminated by adding 100 l of methanol, acidified to pH 4 with
glacial acetic acid and applied to a Strata-X solid-phase extraction cartridge previously preconditioned with 3 ml of methanol
and equilibrated with 3 ml of 20% methanol, 80% H2O. After
washing with H2O, the reaction products were eluted with
methanol and analyzed by LC-MS methods as described below.
Inhibition of 12-LOX by ML355—Human or mouse platelettype recombinant 12-LOX (2 g) was incubated with ML355
(ML355 was purchased from Cayman Chemicals) (1.0 M) in
400 l of 100 mM Tris-HCl buffer (pH 7.2) containing 10%
glycerol at 23 °C for 15 min. 2-AA-LPC or 2-AA-LPE were then
added and the reactions were incubated for various times at
30 °C before termination with acidified methanol. The reaction
products were isolated, concentrated, and purified by solidphase extraction using Strata-X columns as described above
and analyzed by LC-MS as described below.
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Experimental procedures
Expression and purification of human platelet-type 12-LOX
Human platelet-type 12-LOX containing an N-terminal
(His)6 tag was constructed and inserted into the BamHI-HindIII sites of pFastbac1 (Invitrogen) by GenScript. The sequence
and orientation verified the identity of the recombinant pFastBac1 containing human ALOX12, which was transfected into
DH10Bac cells (InVitrogen). The Bac-to-Bac Baculovirus
Expression System (Invitrogen) was subsequently utilized for
bacmid preparation and CellFECTIN-mediated transfection of
Spodoptera frugiperda (Sf9) cells to produce recombinant
baculovirus, which was then amplified and titered by the Neutral Red agar overlay method according to the manufacturer’s
protocol (Invitrogen). Expression of the N-terminal His-tagged
12-LOX was initiated by infection of 100 ml of Sf9 cells (1 ⫻ 106
cells/ml) with recombinant virus at a multiplicity of infection of
1. After incubation for 68 h at 27 °C, the cells were pelleted by
centrifugation at 900 ⫻ g for 10 min at 4 °C, resuspended in 2 ml
of ice-cold hypotonic 0.1 ⫻ PBS with swelling on ice for 2 min.
Swelling was then stopped by addition of 2 ml of ice-cold hypertonic 2⫻ PBS containing 10 mM imidazole (pH 7.4), 40 l of 0.1
M phenylmethylsulfonyl fluoride, and 2 l of 10 mg/ml leupeptin. The Sf9 cells were then sonicated (20 ⫻ 1-s bursts utilizing
a Vibra-cell sonicator at 50% output). After adding 10 l of
DNase I (1.0 unit/l) and 40 l of 20% Tween 20, the Sf9 cells
were sonicated again (10 ⫻ 1-s bursts at 50% output), incubated
for 5 min on ice, and centrifuged at 15,000 ⫻ g for 15 min at
4 °C. The supernatant was removed and the NaCl concentration was adjusted to 300 mM.
Purification of the recombinant 12-LOX was performed
using nickel-nitrilotriacetic acid (Ni-NTA) metal-affinity chromatography per the manufacturer’s protocol (Thermo Scientific number 88225). Briefly, the protein extract was loaded
onto a Ni-NTA column that was pre-equilibrated with 3 ⫻ 10
ml of 2⫻ PBS containing 25 mM imidazole (pH 7.4). After washing the column 6 times with 7.0 ml of 2⫻ PBS containing 25 mM
imidazole (pH 7.4) to remove nonspecifically bound proteins,
the His-tagged 12-LOX was fractionally eluted with 9 ⫻ 1.0 ml
of ice-cold 2⫻ PBS containing 150 mM imidazole (pH 7.4). The
presence of the recombinant 12-LOX was confirmed by ECL
Western blot analysis using an anti-(His)6 mAb.

cPLA2␣(His)6 baculovirus (multiplicity of infection ⬃1).
After incubation at 27 °C for 72 h, the Sf9 cells expressing
cPLA2␣(His)6 were centrifuged (600 ⫻ g for 10 min) to
remove the cell media. The resultant cell pellets were resuspended in 20 ml of lysis buffer (20 mM potassium Pi, pH 8.0,
containing 2 mM imidazole, 10% glycerol, 5 g/ml of leupeptin, 5 g/ml of aprotinin), sonicated (20 –25 bursts, 30%
power), and centrifuged (600 ⫻ g for 5 min). The supernatant
was removed (saved) and the remaining cell pellets were sonicated (20 –25 bursts, 30% power) in an additional 20 ml of
lysis buffer. The cell homogenates were then pooled and centrifuged (100,000 ⫻ g for 1 h) to obtain the cytosolic fraction.
The cytosol containing cPLA2␣(His)6 was diluted 1:1 in 20
mM potassium Pi (pH 8.0), 2 mM imidazole, 500 mM NaCl,
10% glycerol (Buffer A) and applied to a 3 ml of Ni-NTA
column equilibrated with 20 mM potassium Pi (pH 8.0), 2 mM
imidazole, 250 mM NaCl, 10% glycerol (Buffer B). After
washing the column with 30 ml of Buffer A containing 10 mM
imidazole, bound proteins were eluted with 20 mM potassium Pi (pH 8.0), 250 mM imidazole, 500 mM NaCl, 10% glycerol. Eluted proteins were dialyzed overnight against 10 mM
Tris-HCl (pH 8.0) containing 0.1 mM EDTA and 10% glycerol. The dialyzed proteins containing cPLA2␣(His)6 were
next applied to a MonoQ FPLC column equilibrated with the
same buffer. After washing the MonoQ column with 10 mM
Tris-HCl (pH 8.0) containing 0.1 mM EDTA, and 10% glycerol, bound cPLA2␣(His)6 was eluted with a 0 –1.0 M NaCl
linear gradient and assayed for activity using 1-palmitoyl-2[1-14C]arachidonoyl-sn-glycero-3-phosphocholine in the
presence of 50 mM Tris-HCl (pH 7.6) containing 1 mM CaCl2.
Following addition of glycerol to 20%, active fractions were
flash frozen in liquid N2 and stored at ⫺80 °C prior to use.
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Substrate concentration dependence experiments—Human
or mouse platelet-type recombinant 12-LOX (2 g) was incubated with varying concentrations of 2-AA-LPC or 2-AA-LPE
(5 to 80 M) in 400 l of 100 mM Tris-HCl buffer (pH 7.2)
containing 10% glycerol in a 30 °C water bath for 2 min. The
reactions were then terminated, and the reaction products were
analyzed by LC-MS as described below. The kinetic values of
Km and Vmax were determined from a nonlinear least-squares
best-fit of the data to the Michaelis-Menten equation using
GraphPad Prism (GraphPad Software, La Jolla, CA).
Hydrolysis of eicosanoid-lysophospholipids by cPLA2␣ and
identification of the released eicosanoid products

C18 reverse phase HPLC-tandem MS (LC-MSn)
LC-MSn analyses were performed using an LTQ-Orbitrap
mass spectrometer (Thermo Scientific, San Jose, CA) equipped
with a Surveyor HPLC system (Thermo Scientific). Briefly, solid-phase extractions of the 12-lipoxygenase reaction mixtures
utilizing 2-AA-LPC or 2-AA-LPE as a substrate were separated
on a C18 reversed phase column (Ascentis Express, 2.7-m
particles, 150 ⫻ 2.1 mm) at 23 °C using a linear gradient of
solvent A (0.1% glacial acetic acid in water) and solvent B (0.1%
glacial acetic acid in acetonitrile) at a flow rate of 0.2 ml/min.
The following solvent gradient program was used: 0.0 –5.0 min,
25% B; 5.0 –7.0 min, 25–35% B; 7.0 –20.0 min, 35– 60% B; 20.0 –
20.1 min, 60 –100% B; 20.1–28.0 min, 100% B; 28.0 –28.1 min,
100% B to 25% B followed by 10 min isocratic re-equilibration at
25% B. The sample injection volume was 10 l and the
autosampler tray temperature was maintained at 4 °C throughout the analysis. Mass spectrometric analyses were performed
using an LTQ-Orbitrap mass spectrometer. The LTQ ion
source was operated in the positive ion mode at sheath, auxil-

Chiral-phase HPLC-tandem MS
Chiral-phase LC-MSn analyses employing reverse phase LC
were performed using an LTQ-Orbitrap mass spectrometer
(Thermo Scientific) with a Surveyor HPLC system (Thermo
Scientific). Briefly, AMPP-derivatized eicosanoids were injected and separated on a Chiralpak威 AD-RH chiral-phase
HPLC column (5.0-m particles, 150 ⫻ 2.1 mm) at 23 °C using
a linear gradient of solvent A (0.1% glacial acetic acid in water)
and solvent B (0.1% glacial acetic acid in acetonitrile) at a flow
rate of 0.2 ml/min. The following solvent gradient program was
used: 0.0 –1.0 min, 5–22% B; 1.0 –7.0 min, 22–26% B; 7.0 –7.1
min, 26 – 40% B; 7.1–20.0 min, 40 – 60% B; 20.0 –21.0 min,
60 –100% B; 21.0 –29.0 min, 100% B prior to isocratic re-equilibration at 5% B for 10 min. The sample injection volume was 10
l and the autosampler tray temperature was maintained at
4 °C throughout the analysis. Mass spectrometric analysis conditions were identical to those described above under “C18
reverse phase HPLC-tandem MS (LC-MSn).”
General animal studies
Animal protocols were conducted in strict accordance with
the National Institutes of Health guidelines for humane treatment of animals and were reviewed and approved by the Animal Studies Committee of Washington University.
Murine myocardium sample preparation and analysis of
eicosanoid-lysophospholipids
Murine heart tissue samples from control C57BL/6 and
iPLA2␥⫺/⫺ mice (35) were rapidly removed, flash frozen in liquid nitrogen, and stored at ⫺180 °C prior to analysis for eicosanoid-lysophospholipids. Myocardial tissues were extracted
using a modified Bligh and Dyer (56) procedure. Briefly, ⬃40
mg of tissue was extracted by addition of 3 ml of ice-cold
CH3OH/CHCl3 (1:2 (v/v) containing 2% glacial acetic acid) followed directly by addition of 17:0-LPC as an internal standard.
Next, the samples were homogenized using a Polytron homogenizer at 0 – 4 °C and 1 ml of ice-cold H2O was added prior to
separation of the organic and aqueous phases by centrifugation
at 1,500 ⫻ g for 15 min. The CHCl3 layer was transferred to a
new tube, whereas the aqueous layer was re-extracted by subsequent addition of 2 ml of CHCl3, vortexing, and phase separation by centrifugation at 1,500 ⫻ g for 15 min. The CHCl3
J. Biol. Chem. (2020) 295(16) 5307–5320
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The eicosanoid-lysophospholipid products generated by
12-LOX were incubated with purified cPLA2␣ (5 g) in 200 l
of HEPES buffer (10 mM HEPES, pH 7.4, 100 mM KCl, 0.5 mM
CaCl2, and 10% glycerol) for 15 min at 37 °C. Reactions were
stopped by addition of 50 l of methanol followed by acidification of the reaction mixture to pH 4 with glacial acetic acid.
Terminated reactions were immediately applied to a Strata-X
solid-phase extraction cartridge (60 mg/ml) that had been previously preconditioned with 3 ml of methanol followed by
sequential washing with 3 ml of 10% methanol, 90% H2O. After
washing with 3 ml of H2O, the oxidized fatty acid metabolites
were eluted with 2 ⫻ 0.5-ml volumes of methanol containing
1% glacial acetic acid. The combined acidified methanol eluates
were evaporated to dryness using a SpeedVac concentrator
prior to charge-switch derivatization with AMPP. Derivatization with AMPP was performed as previously described (43).
Briefly, 20 l of ice-cold acetonitrile/N,N-dimethylformamide
(4:1, v/v) and 20 l of ice-cold 640 mM (3-(dimethylamino)propyl)ethylcarbodiimide hydrochloride in HPLC grade water
were added to the dried residue in a sample vial. The vial was
briefly vortexed and 40 l of 5 mM N-hydroxyl benzotriazole
and 15 mM AMPP in acetonitrile were added, vortexed, and
placed in a 60 °C water bath for 30 min. Samples were then
analyzed by LC-MSn using “C18 reverse phase HPLC-tandem
MS” and “chiral-phase HPLC-tandem MS” (see below).

iary, and sweep gas flows (arbitrary units) of 40, 5, and 1, respectively. The capillary temperature was set to 275 °C, and the electrospray voltage was 4.1 kV. Capillary voltage and tube lens
voltage were set at 30 and 110 V, respectively. The mass spectrometer was calibrated using the manufacturer’s recommended positive mode calibration solution containing L-methionyl-arginyl-phenylalanyl-alanine acetate, Ultramark 1621,
and caffeine. Resolving powers (at m/z 400 Th) of 30,000 in full
scan mode and in MS/MS mode were used. The mass accuracy
was within 5 ppm at mass values from m/z 130 to 2000. For
MS/MS analyses, a normalized collision energy of 30% was
applied and the activation time was set at 30 ms with an activation parameter of q ⫽ 0.25. Data acquisition was performed
using an Xcalibur operating system, version 2.1 (Thermo
Scientific).
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extracts were combined, evaporated under a nitrogen stream,
and resuspended in 100 l of 80% methanol in water prior to
LC-MS/MS analyses as described above.
Murine serum sample preparation and analysis of
eicosanoid-lysophospholipids
Serum samples from 10- or 3-month-old control C57BL/6
mice and iPLA2␥⫺/⫺ mice (35) were prepared by centrifugation
of the blood collected from submandibular veins at 1,500 ⫻ g
for 10 min after incubation for 30 min at room temperature.
The serum was quickly removed and 10 l of fresh serum were
used for lipid extractions using a modified Bligh and Dyer procedure (56) and analysis by HPLC-MS/MS as described above.
Isolation and activation of platelets

Statistical analysis
Statistical analyses were performed using the two-tailed
Student’s t test. p values of less than 0.05 were considered to be
statistically significant. All data are reported as the mean ⫾ S.E.
unless otherwise noted.
Data availability
All data presented in this paper are contained within the
manuscript.
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Blood from control C57BL/6 and iPLA2␥⫺/⫺ mice (35) was
obtained by intracardiac puncture from euthanized mice.
About 0.8 ml of blood was drawn into a syringe containing 0.15
ml of 3.8% sodium citrate to prevent platelet activation. The
blood was then centrifuged at 150 ⫻ g for 10 min at room
temperature, and the platelet-rich-plasma was subsequently
centrifuged at 250 ⫻ g for 5 min to remove residual red blood
cells. The purified platelet-rich-plasma was spun at 1,500 ⫻
g for 10 min, and the pellet was resuspended in Tyrode’s
buffer containing 0.38% sodium citrate. The platelets were
pelleted by centrifuging at 800 ⫻ g for 10 min, resuspended
in Tyrode’s buffer containing 1.0 mM CaCl2 and incubated at
37 °C in the presence or absence of A23817 (1.0 M) for 15
min. For inhibition experiments, ML355 (10 M) was preincubated with the isolated platelets for 15 min prior to addition of A23187. Lipids were then extracted using a modified
Bligh and Dyer (56) procedure and analyzed by HPLCMS/MS as described above.
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